Cell doublings were normalized to the average of the SLC25A39 knockout cells expressing SLC25A39 cDNA

According to British Society for Haematology (BSH) guidelines and NICE Clinical Knowledge Summaries (CKS), the primary beneficiaries include: Key patient groups who may require B12 injections include: Pernicious anaemia patients requiring lifelong hydroxocobalamin 1mg intramuscularly every 23 months following initial loading doses Patients with gastrointestinal disorders including those who have undergone gastrectomy or ileal resection, and patients with conditions affecting B12 absorption such as Crohn's disease or coeliac disease Strict vegans and vegetarians though oral supplementation is usually sufficient unless malabsorption is present Elderly patients who may have reduced gastric acid production affecting B12 absorption Patients taking certain medications including metformin (MHRA advises monitoring B12 levels in long-term users, particularly those with risk factors or symptoms), proton pump inhibitors, and H2-receptor antagonists long-term [6] Individuals with neurological symptoms such as paraesthesia, ataxia, or cognitive impairment related to B12 deficiency Pregnant women with confirmed deficiency (hydroxocobalamin for malabsorption

doi: 10.1007/s12282-013-0496-9 99 De VitaALiveraniCMolinaroRMartinezJOHartmanKASpadazziCet al
NPR's Yuki Noguchi reports on the possible implications of cycling on and off these drugs
In the late 2000s, still haunted by the fallout from drugs like rosiglitazone (brand name Avandia), linked to increased heart attack risk, the FDA laid down a blunt new rule: every new diabetes drug must prove it wont harm the heart before it ever sees pharmacy shelves